Clinical Trials Logo

LCA (Leber Congenital Amaurosis) clinical trials

View clinical trials related to LCA (Leber Congenital Amaurosis).

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01521793 Completed - Clinical trials for RP (Retinitis Pigmentosa)

Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)

Start date: January 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is: - To evaluate the safety of up to 3 additional courses of oral QLT091001 administered once daily for 7 days in subjects treated previously with a single 7-day course of QLT091001 in Study RET IRD 01 - To evaluate whether up to 3 additional courses of oral QLT091001 administered once daily for 7 days can maintain or improve visual function.

NCT ID: NCT01014052 Completed - Clinical trials for RP (Retinitis Pigmentosa)

Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) Mutations

Start date: November 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is: - to evaluate the safety of oral QLT091001 - to evaluate whether 7-day treatment with oral QLT091001 can improve visual function in subjects with LCA or RP due to RPE65 or LRAT mutations - to evaluate duration of visual function improvement (if observed)